Relapses in the Guillain-Barre syndrome after treatment with intravenous immune globulin or plasma exchange

To clarify the question of whether Guillain-Barre syndrome (GBS) patients treated with intravenous immune globulin (IVIG) relapse at a higher frequency than those treated with plasma exchange (PE), 54 patients with GBS were studied retrospectively. A higher frequency of relapses was noted in the PE-treated patients than in those receiving IVIG. The presence of an associated medical condition correlated with an increased risk of relapses, while earlier onset of treatment resulted in a decrease of relapses of GBS. This study found no support for prior suggestions of increased relapses in patients with GBS treated with IVIG as opposed to those treated with PE.